In recent years, plan sponsors have reaped the benefits of lower prices and increased availability of generic versions of brand-name drugs. At The Value of Generic Drug Symposium, speakers who have different roles in the industry discussed the myriad barriers limiting potential cost savings. Find out what they had to say about bioequivalency, enhanced savings opportunities, the impact of coupon cards and more.
 |
|
The Bank of Canada is facing an increasingly uncertain 2026 despite experts agreeing on its current policy path. Etienne Bordeleau-Labrecque, vice-president and portfolio manager at...
Running for 20 years, Benefits Canada’s 2025 Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. This year, attendees...
As Canada navigates the evolving drug coverage landscape, private drug plans remain a cornerstone of access, innovation and economic growth. Indeed, private drug plans are...
As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors, according...
It took Peter Deitz eight years to figure out the best way to sell his business. But it wasn’t until the federal government opened up...
A smooth return to office begins with clarity around the purpose of time in the office, as well as meaningful leadership presence, says Courtney Elling,...
The Association for Canadian Pension Management is asking the Ontario government to introduce variable life benefits in Ontario and to align its pension rules with...
The University Pension Plan Ontario is creating a joint venture with Schroders Capital to invest in high-quality logistics and industrial real estate across northwestern Europe....
